Clinical trial
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2…
NCT00153023 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153023 |
|---|---|
| Title | 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy |
| Official title | A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathies, Hypertension |
| Intervention type | Drug |
| Interventions | Telmisartan, Valsartan |
| Enrollment | 885 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 13, 2013 |
| Countries | Czechia, Denmark, France, Germany, Italy, Malaysia, Portugal, Russia, Slovakia, South Korea, Spain, Taiwan and 1 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: